{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:22:03Z","timestamp":1761970923714,"version":"build-2065373602"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,9,27]],"date-time":"2012-09-27T00:00:00Z","timestamp":1348704000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cardiothorac Surg"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Individuals with implanted mechanical valve prostheses require lifelong anticoagulation therapy with warfarin. The narrow therapeutic index of warfarin makes it difficult to dose and maintain proper anticoagulation. A number of single nucleotide polymorphisms (SNPs) affecting vitamin K or warfarin metabolism have been shown to affect warfarin dosing. Our aim was to study the effect of the CYP4F2 rs2108622-1347 (C\u2009&gt;\u2009T) variant on warfarin dosing in Chinese patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We studied 352 patients after heart valve replacement surgery. Warfarin dosing for patients was adjusted to achieve 1.8 \u2264 INR\u2009\u2264\u20092.5. We determined the presence of SNPs in CYP4F2 in these patients and investigated their association with warfarin dosing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found the frequency of the CYP4F2 rs2108622 C allele was 79.5% and T-allele frequency was 20.5%. The warfarin dose requirement for CC individuals was significantly lower than that for CT or TT individuals (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). TT-homozygous individuals required a 0.56 mg\/day higher dose of warfarin than their CC counterparts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study demonstrates that CYP4F2 rs2108622 significantly affects the warfarin dose requirement to achieve adequate anticoagulant activity in Chinese individuals. Genotyping of this SNP may allow clinicians to determine the initiation dose for patients following valve-replacement surgery in China.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1749-8090-7-97","type":"journal-article","created":{"date-parts":[[2012,9,27]],"date-time":"2012-09-27T21:57:30Z","timestamp":1348783050000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Correlation between single nucleotide polymorphisms in CYP4F2 and warfarin dosing in chinese valve replacement patients"],"prefix":"10.1186","volume":"7","author":[{"given":"Jie-Hui","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Guo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Qiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Bing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Jun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,9,27]]},"reference":[{"key":"610_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/jbm.b.31151","volume":"88","author":"AG Kidane","year":"2009","unstructured":"Kidane AG, Burriesci G, Cornejo P, Dooley A, Sarkar S, Bonhoeffer P, Edirisinghe M, Seifalian AM: Current developments and future prospects for heart valve replacement therapy. J Biomed Mater Res B Appl Biomater. 2009, 88: 290-303.","journal-title":"J Biomed Mater Res B Appl Biomater"},{"key":"610_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s10741-008-9115-9","volume":"15","author":"I Glurich","year":"2010","unstructured":"Glurich I, Burmester JK, Caldwell MD: Understanding the pharmacogenetic approach to warfarin dosing. Heart Fail Rev. 2010, 15: 239-248. 10.1007\/s10741-008-9115-9.","journal-title":"Heart Fail Rev"},{"key":"610_CR3","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1089\/104454999315006","volume":"18","author":"Y Kikuta","year":"1999","unstructured":"Kikuta Y, Miyauchi Y, Kusunose E, Kusunose M: Expression and molecular cloning of human liver leukotriene B4 omega-hydroxylase (CYP4F2) gene. DNA Cell Biol. 1999, 18: 723-730. 10.1089\/104454999315006.","journal-title":"DNA Cell Biol"},{"key":"610_CR4","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMc1012980","volume":"364","author":"E Arellano-Rodrigo","year":"2011","unstructured":"Arellano-Rodrigo E: Home monitoring of warfarin effects. N Engl J Med. 2011, 364: 378-379.","journal-title":"N Engl J Med"},{"key":"610_CR5","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1378\/chest.127.6.2049","volume":"127","author":"D Garcia","year":"2005","unstructured":"Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM: Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest. 2005, 127: 2049-2056. 10.1378\/chest.127.6.2049.","journal-title":"Chest"},{"key":"610_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/GIM.0b013e31815bf924","volume":"10","author":"MR McClain","year":"2008","unstructured":"McClain MR, Palomaki GE, Piper M, Haddow JE: A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. Genet Med. 2008, 10: 89-98. 10.1097\/GIM.0b013e31815bf924.","journal-title":"Genet Med"},{"key":"610_CR7","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2217\/14622416.8.7.713","volume":"8","author":"K Nakai","year":"2007","unstructured":"Nakai K, Tsuboi J, Okabayashi H, Fukuhiro Y, Oka T, Habano W, Fukushima N, Nakai K, Obara W, Fujioka T, Suwabe A, Gurwitz D: Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients. Pharmacogenomics. 2007, 8: 713-719. 10.2217\/14622416.8.7.713.","journal-title":"Pharmacogenomics"},{"key":"610_CR8","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1182\/blood-2005-03-1108","volume":"106","author":"EA Sconce","year":"2005","unstructured":"Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005, 106: 2329-2333. 10.1182\/blood-2005-03-1108.","journal-title":"Blood"},{"key":"610_CR9","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/j.thromres.2009.10.017","volume":"125","author":"L Yang","year":"2010","unstructured":"Yang L, Ge W, Yu F, Zhu H: Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement\u2013a systematic review and meta analysis. Thromb Res. 2010, 125: e159-e166. 10.1016\/j.thromres.2009.10.017.","journal-title":"Thromb Res"},{"key":"610_CR10","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1182\/blood-2007-11-122010","volume":"111","author":"MD Caldwell","year":"2008","unstructured":"Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, King CR, Brower A, Schmelzer JR, Glurich I, Vidaillet HJ, Yale SH, Qi Zhang K, Berg RL, Burmester JK: CYP4F2 genetic variant alters required warfarin dose. Blood. 2008, 111: 4106-4112. 10.1182\/blood-2007-11-122010.","journal-title":"Blood"},{"key":"610_CR11","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1365-2125.2010.03698.x","volume":"70","author":"HJ Cen","year":"2010","unstructured":"Cen HJ, Zeng WT, Leng XY, Huang M, Chen X, Li JL, Huang ZY, Bi HC, Wang XD, He YL, He F, Zhou RN, Zheng QS, Zhao LZ: A minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br J Clin Pharmacol. 2010, 70: 234-240. 10.1111\/j.1365-2125.2010.03698.x.","journal-title":"Br J Clin Pharmacol"},{"key":"610_CR12","doi-asserted-by":"publisher","first-page":"e1000433","DOI":"10.1371\/journal.pgen.1000433","volume":"5","author":"F Takeuchi","year":"2009","unstructured":"Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, Holm L, Lindh J, Rane A, Wadelius M, Deloukas P: A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009, 5: e1000433-10.1371\/journal.pgen.1000433.","journal-title":"PLoS Genet"},{"key":"610_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/clpt.2009.178","volume":"87","author":"E Pautas","year":"2010","unstructured":"Pautas E, Moreau C, Gouin-Thibault I, Golmard JL, Mah\u00e9 I, Legendre C, Taillandier-H\u00e9riche E, Durand-Gasselin B, Houllier AM, Verrier P, Beaune P, Loriot MA, Siguret V: Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther. 2010, 87: 57-64. 10.1038\/clpt.2009.178.","journal-title":"Clin Pharmacol Ther"},{"key":"610_CR14","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/j.1538-7836.2010.03800.x","volume":"8","author":"V P\u00e9rez-Andreu","year":"2010","unstructured":"P\u00e9rez-Andreu V, Rold\u00e1n V, L\u00f3pez-Fern\u00e1ndez MF, Ant\u00f3n AI, Alberca I, Corral J, Montes R, Garc\u00eda-Barber\u00e1 N, Ferrando F, Vicente V, Gonz\u00e1lez-Conejero R: Pharmacogenetics of acenocoumarol in patients with extreme dose requirements. J Thromb Haemost. 2010, 8: 1012-1017.","journal-title":"J Thromb Haemost"},{"key":"610_CR15","doi-asserted-by":"publisher","first-page":"739751","DOI":"10.1155\/2011\/739751","volume":"2011","author":"MK Kringen","year":"2011","unstructured":"Kringen MK, Haug KB, Grimholt RM, Stormo C, Narum S, Opdal MS, Fosen JT, Piehler AP, Johansen PW, Seljeflot I, Berg JP, Br\u00f8rs O: Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction. J Biomed Biotechnol. 2011, 2011: 739751-","journal-title":"J Biomed Biotechnol"},{"key":"610_CR16","doi-asserted-by":"publisher","first-page":"851","DOI":"10.2217\/14622416.8.7.851","volume":"8","author":"AH Wu","year":"2007","unstructured":"Wu AH: Use of genetic and nongenetic factors in warfarin dosing algorithms. Pharmacogenomics. 2007, 8: 851-861. 10.2217\/14622416.8.7.851.","journal-title":"Pharmacogenomics"},{"key":"610_CR17","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1124\/mol.109.054833","volume":"75","author":"MG McDonald","year":"2009","unstructured":"McDonald MG, Rieder MJ, Nakano M, Hsia CK, Rettie AE: CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol. 2009, 75: 1337-1346. 10.1124\/mol.109.054833.","journal-title":"Mol Pharmacol"},{"key":"610_CR18","doi-asserted-by":"publisher","first-page":"e259","DOI":"10.1016\/j.thromres.2009.11.020","volume":"125","author":"PS Wells","year":"2010","unstructured":"Wells PS, Majeed H, Kassem S, Langlois N, Gin B, Clermont J, Taljaard M: A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism. Thromb Res. 2010, 125: e259-e264. 10.1016\/j.thromres.2009.11.020.","journal-title":"Thromb Res"},{"key":"610_CR19","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.2217\/pgs.09.106","volume":"10","author":"MT Lee","year":"2009","unstructured":"Lee MT, Chen CH, Chou CH, Lu LS, Chuang HP, Chen YT, Saleem AN, Wen MS, Chen JJ, Wu JY, Chen YT: Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics. 2009, 10: 1905-1913. 10.2217\/pgs.09.106.","journal-title":"Pharmacogenomics"},{"key":"610_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.thromres.2011.11.043","volume":"130","author":"R Liang","year":"2011","unstructured":"Liang R, Wang C, Zhao H, Huang J, Hu D, Sun Y: Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis. Thromb Res. 2011, 130: 38-44.","journal-title":"Thromb Res"}],"container-title":["Journal of Cardiothoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1749-8090-7-97.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1749-8090-7-97\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1749-8090-7-97","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1749-8090-7-97.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T23:52:38Z","timestamp":1687737158000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiothoracicsurgery.biomedcentral.com\/articles\/10.1186\/1749-8090-7-97"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,27]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["610"],"URL":"https:\/\/doi.org\/10.1186\/1749-8090-7-97","relation":{},"ISSN":["1749-8090"],"issn-type":[{"type":"electronic","value":"1749-8090"}],"subject":[],"published":{"date-parts":[[2012,9,27]]},"assertion":[{"value":"15 June 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"97"}}